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The neutrophil enzymes, proteinase 3 and elastase, enhance the
production of interleukin-8 by endothelial cells in culture. S.P. Berger,
M.A.J. Seelen, P.S. Hiemstra, F. Heemskerk, F.J. van der Woude, and M.R.
Daha, Department ofNephrology, University Hospital Leiden, Leiden, The
Netherlands. The discovery of the neutrophil lysozomal enzyme proteinase
3 (PR3) as the major target antigen of anti-neutrophil cytoplasmic
antibodies (ANCA) in Wegener's granulomatosis has stimulated strong
interest in the enzyme's role as a potential effector in systemic vasculitis.
The lesions of the acute phase of vasculitis are dominated by polymor-
phonuclear neutrophils (PMN) infiltrating into the vessel wall. Activation
of PMN leads to degranulation and release of PR3 which binds to
endothelial cells in vitro and is recognized by ANCA on thc cellular
membrane. Depositions of PR3 have been detected on the glomerular
basement membrane and endothelium in kidney biopsies from patients
with Wegener's granulomatosis. In the present study we questioned
whether neutrophil lysosomal enzymes, once released at the site of
inflammation, are able to potentiate the influx of additional PMN's by
enhancing the production of the chemotactic cytokine IL-8. Therefore,
human umbilical vein endothelial cells (HUVEC) in culture were incu-
bated with varying concentrations of highly purified proteinase 3 (PR3),
HNE (human neutrophil elastase) and cathepsin G for different time
periods. The supernatants were subsequently assessed for IL-8 antigen
using a sandwich ELISA. HUVEC in culture produced 350 pg IL-8/ml in
24 hours. The presence of PR3 and HNE in concentrations ranging from
3 to 0.1 jsg/ml enhanced TL-8 production, up to 20- and 5-fold, respec-
tively, in a dose- and time-dependent fashion. Cathcpsin G did not
influence JL-8 production. While the addition of al-proteinase inhibitor
completely abrogated HNE-mediated IL-8 production, it did not signifi-
cantly influence the effect of PR3 on IL-8 production. The effect of PR3
was inhibited by cycloheximide indicating de nova synthesis of IL-8. We
postulate that the neutrophil lysosomal enzymes PR3 and HNE may
contribute to a self-perpetuating process of neutrophil recruitment in
systemic vasculitis, for example, Wcgener's Granulomatosis, by increasing
de nova synthesis of IL-8 by endothelial cells. PR3 is a more powerful
mediator of IL-8 production than HNE and exerts its effect independently
of its enzymatic activity.
Nucleosomes and histones are present in glomerular deposits in human
lupus nephritis. M. van Bruggen, C. Kramers, B. Walgreen, J. Elema, C.
Kallenberg, J. van de Born, R. Smeenk, K. Assmann, S. Muller, M. Monestier,
and J. Berden, Division of Nephrology, Department of Pathology, University
Hospital Nijmegen, Department of Pathology and Clinical Immunology,
University Hospital Groningen, and Department of .4utoimmune Diseases,
CLB, Amsterdam, The Netherlands; Institut de Biologic Moléculaire et
Cellulaire, CNRS, Strasbourg, France; Department of Immunology, Temple
University, Philadelphia, Pennsylvania, USA. Recently, we showed that
anti-nuclear autoantibodies complexed to nucleosomes can bind to hepa-
ran sulfate (HS) in the glomerular basement membrane (GBM) via
interaction of the histone part of the nucleosome. Histones have been
identified in glomerular deposits in human and murine lupus nephritis,
and a decreased HS staining was found in human and murine lupus
nephritis, most likely due to masking by deposition of antibodies corn-
plexed to nucleosomes. In this study we questioned first whether nucleo-
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sornes could be identified in glomerular deposits in human lupus nephritis
and secondly whether the presence of histones or nucleosomes was
correlated with absence of HS staining. Kidney biopsies of SLE patients
and non-SLE controls were stained for histones, DNA, nucleosomes, lgG,
HS and heparan sulfate proteoglyean (HSPG) core protein. In the table
the number of biopsies positive for nueleosomes, DNA or histones in
glomerular deposits is given.
Antibodies
SLE n
DPGNU
Class IV
ephritis
MGN"
Class V
Non-SLE
MCGNC
nephritis
MGNh
Anti-nucleosorne" 5/11 0/6 0/4 0/5
Anti-dsDNA" 0/11 0/6 0/4 0/5
Anti-histone" 6/11 2/6 0/4 0/5
Polyelonal anti-H3 (1-21) 11/11" 2/6 1/4 0/5
Diffuse proliferative glomerulonephritis; h Membranous glomerulone-
phritis; Mesangiocapillary glomerulonephritis; d Monoclonal antibodies;
P < 0.01, Fisher exact test
HS staining was nearly absent in DPGN, whereas staining was only
moderately reduced in patients with MGN and controls (P = 0.01,
Mann-Whitney U test). In conclusion, using the polyclonal anti-H3
antiserum, histones were identified in all patients with DPGN and their
presence was associated with a decrease of HS staining. Nucleosomes were
identified in 5 Out of 11 patients with DPGN. In all other patients
nucleosomes were not detected. This is the first demonstration of nucleo-
somes in glomerular deposits in SLE nephritis. It remains to he elucidated
whether the nueleosornal particle deposited in these lesions consists
mainly of histones or that nucleosome specific epitopes are masked by
anti-nucleosome and/or anti-dsDNA autoantibodics bound in viva to these
epitopes.
Altered expression of glomerular ectonucleotidase in kidney grafts with
delayed function. O.L.W.B. van Balen, W. van Son, F. Wit, and WW
Bakker, Departments of Pathology and Clinic far Internal Medicine, Division
of Nephrology, University Hospital Groningen, Graningen, The Netherlands.
In allografts isehemic damage of the mierovasculature frequently oeeurs
following renal transplantation (RTX) and is associated with chronic graft
failure. Evidence is accumulating that reactive oxygen species (ROS)
might play an important role in the pathogenesis of this injury. From
animal experiments it is known that vessel wall associated ecto-enzymes,
such as glomerular eeto-ATPase, are very sensitive to ROS, in contrast to
5'-ectonucleotidase, whieh enzyme shows enhanced expression in ischemic
conditions. Therefore, it is conceivable that also in humans ischemic injury
may be reflected by diminished expression of ecto-ATPase and by an
increased expression of 5'-ectonucleotidase. To study the possible rela-
tionship between glornerular ecto-nucleotidase expression and renal allo--
graft function, we studied 23 biopsies of RTX patients taken after rena'
revascularization and compared ecto-enzyrne staining on 10 patients with
immediate graft function (IF) with 13 patients with delayed graft function
(DF). No significant differences were found in ischernia times or preser-
vation procedures between the IF and the DF grafts. Unfixed cryostat
sections from biopsies were stained using a mouse monoclonal antibody
against ATP-diphosphorylase and rabbit anti-mouse 1gM peroxidase as a
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second step; 5'-ectonuclcotidase activity was detected by conventional
enzymhistochemical staining. Reaction products were quantified (double-
blind) and expressed in units per glomerulus using computerized image
analysis. Mean amounts of reaction product scored in approximately six
glomeruli per individual were statistically evaluated. The DF group versus
the IF group showed in the ATPase staining decreased expression of
glomerular reaction products (31.7 8.6 vs. 44.2 5.4, means SCM, P <
0.01, Mann Whitney U test) whereas increased activity was detected using
the 5'-nucleotidase staining (27.0 4.2 vs. 20.7 4.2, P < 0.05, Wilcoxon
test). We conclude that delayed graft function after RTX is associated
with a diminished ecto-ATPase expression and an increased 5'-eetonucle-
otidase activity. Although a possible causal relationship between glomer-
ular eeto-enzyme expression and graft function cannot be concluded from
these data, it is clear that expression of glomerular ecto-nucleotidase may
be considered as an early marker for oxygen dependent injury of the
human kidney.
The level of albuminuria at the start of ACE-inhibitor treatment
determines the long-term renal outcome in Fawn-Hooded (FH) rats. A. P.
Provoost, G.H. Verseput, and HA. Koomans, Department of Pediatric
Surgeiy, Erasmus University, Rotterdam, and Department of Nephrology,
University Hospital, Utrecht, The Netherlands. Early treatment with an
angiotensin converting enzyme-inhibitor (ACE-i) has been found to be
very effective in preventing proteinuria and renal damage in experimental
renal disease. However, little is known about the effects of ACE-i when
renal damage is more advanced. Inbred male FH rats spontaneously
develop systemic and glomerular hypertension, progressive albuminuria
(UAV), and glomerulosclerosis at a young age, resulting in terminal renal
failure. They were used to study the effects of lisinopril (US; 50 mg/liter
drinking water) on systolic blood pressure (SBP) and UAV. US was
started at 7, 22, 36, or 50 weeks of age. In surviving animals the follow-up
was stopped at 72 weeks of age. Median survival time of all untreated FH
rats (N = 58) was 52 weeks. LIS started at 7 weeks of age (N = 10),
completely prevented the increase in SBP and the development of UAV,
and all rats survived until 72 weeks. Ten rats treated from week 22, with
an initial SBP and UAV of 166 6 mm Hg (mean SD) and 198 56
mg/day, showed a normalization of SBP and UAV after 4 weeks of LIS.
SBP remained normotensive during follow-up, but from week 40 most rats
showed a moderate to marked increase in UAV. After 3 weeks of US,
starting at 36 weeks of age (N = 12), SBP fell from 163 13 to 110 12
mm Hg, and UAV from 371 122 to 112 90 mg/day. The UAV
response was quite variable, mainly depending on the level of UAV before
LIS and not on the fall in SBP. During follow-up, 6 rats (those with the
highest UAV after 3 weeks on LIS) died prematurely from renal failure.
A similar outcome was noted when treatment was started at 50 weeks of
age (N 9). SBP fell from 161 9 to 110 16mm Hg, UAV from 342
103 to 142 114 mg/day after 3 weeks of US. Five rats, again those with
the highest UAV after LIS, died before the end of follow-up. We conclude
that early start of ACE-i is essential for complete renal protection.
Although a later start reduces UAV, there appears to be some degree of
irreversible impairment of the permselective properties of the glomerular
filtration barrier. At these stages, the rate of progression of renal damage
can still be slowed down and survival time prolonged.
Angiotensin II (Aug II) mediates the up-regulation of aminopeptidase
A (APA) mRNA expression in an experimental model of membranous
giomerulonephritis. S. Mentzel, AS. de Jon H.B.P.M. D4/kman, J.P.H.F.
van Son, J.F.M. Wetzels, RAP. Koene, and KiM. Assmann, University
Hospital Nijmegen, Nijmegen, The Netherlands. APA, a hydrolase present
on glomerular visceral cpithelial cells and brush borders of the proximal
tubular epithelial cells, plays an important regulatory role in the renin-
angiotensin system by its peptidolytic action on Ang TI. Injection of a mAb
against APA (ASD-4), that blocks the enzyme activity in vivo, induces an
acute albuminuria. Previously, we have shown that Ang ii plays a major
role in the acute albuminuria in this model, since both enalapril and
losartan considerably reduce the acute albuminuria. In this model we have
studied the regulation of renal APA mRNA by a competitive PCR assay.
As an internal standard in this assay we created a 52 base pair deletion
product of APA eDNA that served as a competitor molecule. The ratio
between the internal standard and the normal PCR product was calculated
using the VIDASI" image analysis system. In addition, we have used an
in situ hybridization technique. By competitive PCR we found that APA
mRNA [expressed in 106 mRNA molecules/.rg total RNA (mean SEM)1
was significantly up-regulated after injection of ASD-4: 20.8 2.0 versus
12.4 1.2 (controls). Enalapril completely prevented this increase (14.6
1.2). In contrast, losartan increased APA mRNA in control mice (29.0
5.6), with no further increase being observed in mice treated with ASD-4
and losartan (28.4 3.4). RNA in situ hybridization on light and electron
microscopical level demonstrated in all groups strong APA mRNA
expression in the glomerular visceral epithelial cells, but virtually none in
the proximal tubules. No differences in APA mRNA expression could be
shown in the different experimental groups by in situ hybridization, which
is probably due to the insensitivity of this technique in comparison with the
competitive PCR assay. Conclusion: APA mRNA expression in mouse
kidneys can be influenced by procedures that have an effect on the local
Ang H levels. This strongly suggests that Aug II directly regulates the renal
APA mRNA expression.
Glycine and acidosis reduce hypoxia-induced protease activity in rat
proximal tubules. M.J.H. Tijsen, S.M.A. Peters, RiM. Bindels, C.H. van Os,
and J.F.M. Wetzels, Department of Cell Physiology, University of Nijmegen,
and Department of Nephrology, University Hospital Nijmegen, Ntjmegen, The
Netherlands. Both glycine and acidosis afford protection against hypoxic
injury in isolated rat proximal tubules, hut the precise mechanisms remain
unknown. Glycine was reported to inhibit calpain-like protease activity in
isolated hepatocytes during anoxia. We studied the effect of hypoxia,
glycine and acidoses on the activities of the four classes of proteases in rat
proximal tubules. Freshly-isolated rat proximal tubules were incubated for
15 minutes in a modified Krebs-Henseleit buffer gassed with 95% 02/5%
CO2 (normoxia) or 95% N2/5% CO2 (hypoxia). Protease activity was
determined as the release of 7-amino-4-methylcoumarin (AMC) from
specific substrates. Hypoxia caused plasma membrane injury, as assessed
by LDH release and decreased intracellular K [Kj1 levels. Glycine (2
mM) completely prevented the hypoxia-induced LDH release, but did not
affect [K] levels. Hypoxia stimulated the activity of serine proteases
(control 108 12 vs. hypoxia 196 18 pmol AMC/mg protein/15 mm,
means su, P < 0.01) and aspartic proteases (control 126 17 vs.
hypoxia 252 16 pmol AMC/mg protein/is mm, < 0.01). Also, calpain
activity increased during hypoxia (control 144 26 vs. hypoxia 438 70
pmol AMC/mg protein/15 mm, P < 0.01). Glycine attenuated hypoxia-
induced calpain activity (289 23 pmol AMC/mg protein/IS mm, p < 0.05
vs. hypoxia). It also reduced metalloprotease activity (control 4229 150,
hypoxia 4680 215, glycine 3798 177 pmol AMC/mg protein/S mm, P <
0.01), but had no effect on the hypoxia-induced increases in serine or
aspartic protease activity. Acidosis protected against hypoxic membrane
damage (hypoxia 62 5% vs. acidosis 33 8% LDH release, P < 0.01).
Hypoxic [K} levels were unaltered. Acidosis had no effect on calpain
activity, but decreased serine protease activity in both normoxic and
hypoxic conditions (normoxia 122 28 vs. acidosis 36 3 and hypoxia
180 22 vs. acidosis 100 9 pmol AMC/mg protein/is mm, P < 0.05).
In conclusion, the data suggest that the mechanism of glycine protection
involves inhibition of hypoxia-induced calpain activity.
Urinary content of Aquaporin 1 and 2 in nephrogenic diabetes insipi.
dus. P.M T Deen, R.A.M.H. van Aubel, A.F. van Lieburg, and Carel H. van
Os, Departments of Cell Physiology and Paediatrics, University of Nijmegen,
Nijmegen, The Netherlands. Congenital nephrogenic diabetes insipidus
(NDI), a recessive hereditary disorder, is caused by mutations in either the
X-ehromosomal gene encoding vasopressin V2-receptor (V2R) or in the
autosomal gene encoding aquaporin-2 (AQP2). Expressed in Xenopus
oocytes, NDI-encoded mutant AQP2 proteins have been shown to be less
stable than wild-type AQP2. We studied the in vivo stability of mutant and
wild-type AQP2 and AQP1 proteins by measuring the excretion in urine in
NDI and healthy individuals. On immunoblots, protein equivalents of
urine samples of healthy volunteers revealed clear AQPI and AQP2
signals in antidiuretie, but not in diuretic states. Furthermore, immuno-
blotting revealed more Tamm-Horsfall protein in antidiuretic compared
to diuretic urine samples. The presence of more low molecular weight
proteins (LMWP) in diuretic urine, as detected on a Coomassie-stained
gel, presumably compensates for relative absence of tubular proteins. In
the urine of a female patient, whose NDI is explained by skewed
inactivation of wild-type V2R, AQP2 excretion was high and comparable
to that in a healthy individual in an antidiurctic state. In the urine of a
male patient with a mutation in the V,R gene a weak AQP2 signal was
detected, which suggests that, as in rats, AQP2 synthesis is induced by
vasopressin. In NDI patients with mutations in AQP2 genes, AQP2 could
Abstracts 1769
not be detected in urine, suggesting a low stability of mutant AQP2
proteins. In five Out of eight NDI patients, AQP1 excretion was relatively
high, which suggests a compensatoly increase in proximal reabsorption in
NDT, possibly mediated by medication.
Mouse podocytes in culture express aminopeptidase A (APA), but not
other components of the renin-angiotensin system (RAS). S. Mentzel,
J.P.H.F. van Son, H.B.P.M. Dijkman, AS. de Jong, M.J.M. Bosch, J.F.M.
Wetzels, RAP. Koene, and KJ.M Assmann, University Hospital Nzjmegen,
The Netherlands. Injection of antibodies (Ab) against podocytic antigens
leads to the induction of a membranous glomerulonephritis in several
species. To study the interaction of Ab with antigens on the podocytes in
vitro we cultured podocytes derived from isolated mouse glomeruli. In
order to use cultured podocytes as an in vivo model, it is important to
establish a cell line of visceral (podocyte) and not of parietal origin.
Previously we have described the characterization of a mouse glomerular
epithelial culture that showed characteristics of podocytes, such as the
expression of the highly podocyte specific antigen ASD-33. In the prcsent
study we have examined the mRNA expression of several RAS compo-
nents and components indirectly coupled to the RAS component angio-
tensin II (Ang II) in the podocytic culture by RT-PCR analysis. We only
found expression for the Ang II degrading hydrolase APA, hut not for any
other RAS component, such as angiotensinogen, angiotensin converting
enzyme, renin, or the Ang II receptors ATIa, and AT2. RT-PCR for the
RAS components on total kidney RNA, however, was positive, indicating
the validity of the RAS primers used. We also observed expression of
dipeptidyl peptidase IV, a hydrolase with a comparable localization to
APA. Strong expression was seen for the extracellular matrix (ECM)
components fibronectin, perlecan, laminin 2b, and collagen IVal, and
weaker expression was observed for the growth factors PDGF, TGFP, and
IL-7. Given these characteristics, this podocytic culture is suitable to study
the interaction between Ang II and APA and the interference of anti-APA
Ab with this process. This is of interest in light of our previous observa-
tions that injection of mice with anti-APA Ab caused acute albuminuria.
Renal plasminogen activator inhibitor type 1 (PAl-i) distribution and
blood lipids in cyclosporin (C5A)-treated rats. C. Duymelinck, GA.
Vetpooten, and M.E. Dc Broe, Department of Nephrology, University of
Antwerp, Antwerp, Belgium. Chronic nephrotoxicity, hypercholesterolemia
and hypofibrinolysis (elevation of plasma PAT-i levels) are major side-
effects of long-term CsA use. Since the rat is known to be very resistant to
the development of vascular lesions, CsA-treated rats were fed a choles-
terol-enriched diet, in an attempt to elevate low density lipoprotein
cholesterol (LDL Chol) and oxidized LDL (0xLDL) levels and to aggra-
vate CsA-induced lesions. Since increased systemic or local PAT-i levels
have been implicated in a number of fibrotic pathologies and in renal
diseases associated with fibrin deposits, the renal distribution of PAl-i was
assessed in a model for CsA-induced nephrotoxicity in the rat. Male
Wistar rats were randomly assigned to a sodium-deficient diet, enriched
with 2% cholesterol (Chol+), or a sodium-deficient cholesterol-free diet
(Chol—). After 9 weeks, both groups were again subdivided in a CsA-
treated (C5A+, 15 mg/kg s.c. daily) and a vehicle-treated (CsA—) group.
After 3 weeks, the rats of all 4 groups (N = 7) were sacrificed. CsA
whole-blood levels were significantly lower in the Chol+CsA+ (4334
1003 ng/ml) than in the Chol—CsA+ group (6092 548 ng/ml). Renal
failure induced by CsA was enhanced by Chol feeding, as shown by the
significantly higher serum ercatinine levels in the Chol+CsA± (1.3 0.2
mg/dl) versus the Chol—CsA+ group (0.9 0.2 mg/dl). In the vehicle-
treated groups no morphological lesions were found. In the CsA-treated
groups, tubular atrophy and ECM deposition were not influenced by Chol
feeding. CsA treatment significantly raised serum triglyceride (TGL)
levels (Chol+CsA+: 126.8 24.7 mg/dl; Chol+CsA—: 51.0 20.8 mg/dl;
Chol—CsA+: 232.4 107.7 mg/dl; Chol—CsA—: 76.3 35.9 mg/dl). Chol
feeding decreased serum HDL Chol levels (Chol+C5A+: 31 14 mg/dl;
Chol—CsA+: 63 9 mg/dl; Chol+CsA—: 39 17 mg/dl; Chol—CsA—:
57 5 mg/dl). In both controls and CsA-treated rats, PAl-i staining was
mainly found in intracellular granules in proximal tubular cells. Compared
to controls, the staining pattern in CsA+ rats proved to be more patchy,
with very dense intracellular granules extending up to the subcapsular foci
of tubulointerstitial damage. Ranking of the PAT-i stained sections
pointed towards an increase of PAl-i in rat kidneys after Chol feeding and
CsA treatment. Tn conclusion, a 3 week CsA treatment increases ECM
deposition, tubular atrophy and serum TGL and influences renal PAT-i
distribution.
Characteristics of an endogenous ACE-inhibitor in tissue homogenates
and urine of the rat. J. Koiter, G.J. Navis, P.E. de Jong, WH. van Gust, and
D. de Zeeuw, GUIDE, University Hospital, Groningen, The Netherlands. The
control of Ang II generation in tissue is still a matter of controversy, in
particular regarding the role of tissue ACE. Earlier we reported that
endogenous ACE-inhibitors may be present in tissue homogenates and
urine, but not in serum of the rat. The present study was designed to prove
the presence of such inhibitor(s) and to further characterize them. Dialysis
(10 kDa membrane) removed inhibitor activity from tissue homogenates:
ACE-activity in kidney, aorta, lung, and left ventricle increased to 168,
139, 221, and 128% of predialysis values, respectively. The removal of
inhibitor activity from the homogenates was confirmed by the fact that the
activity of purified ACE added to the dialysates was inhibited by 50 13%
(SE) for the tissues averaged. Interestingly, urine and its dialysate, which
both contained no converting enzyme, also possessed inhibitor activity: in
fact, added ACE was completely inhibited. In agreement with earlier
findings, no inhibitor activity was found in serum or its dialysates. Inhibitor
activity from kidney homogenate was not affected by five minutes of
boiling. Exposure of the homogenates to the sulfhydryl oxidizing agent
diamidc dose-dependently increased ACE-activity to plateau values of
267 60% averaged for the tissues (3 mvt diamide, N = 6, corrected for
the effect of diamide on purified ACE). In conclusion, an inhibitor of ACE
is present in rat tissues and urine. This inhibitor is characterized as a
molecule smaller than 10000 molecular wt, has a non-protein character,
and is sensitive to oxidation. Possible candidates could be glutathione-like
peptides. The (patho-)physiological significance of such an endogenous
ACE-inhibitor(s) remains to be proven.
Comparison of neutrally and enteric-coated calcium acetate in hemo-
dialysis patients. J.P. l'V. van den Bergh, B. C. Kaufmann, G.J.A. van Riet,
HA.J. Klaassen, W.M. Bottger, and V.M.C. Verstappen, St. Maartens Hos-
pital, Venlo, The Netherlands. Calcium acetate (CaAc) is an effective but
poorly tolerated phosphate binder. Therefore, we developed two different
formulations of CaAc: a neutrally coated tablet (NCCaAc) that easily
disperses pH independently, and an enteric-coated tablet (ECCaAc) that
disperses when pH > 6.5. Each tablet contains 500 mg CaAc (115.5 mg
elementary calcium). In a randomized double-blind crossover study, we
compared efficacy and tolerability of these new drugs in 16 stable
hemodialysis patients. Both drugs were given (with meals) as sole phos-
phate binder for a period of 6 weeks after a control period of 6 weeks with
CaCO3 (N = 16) and Al(OH)3 (N = 3). Blood samples for Ca and P04
were collected weekly just before the first dialysis of the week. The
dialysate calcium (1.3 mmol/liter) and the dose of alphaealcidol (N = 7)
were kept constant. The dietary content of phosphate and calcium
remained constant throughout the study. Results (mean SEM) are given
in the table below:
NCCaAC ECCaAc
1.07 0.10
2.43 0.04
1.97 009,h
IS 6
1.00 0.08
4.3%
7.6%
The incidence of side effects, evaluated by weekly interviews, was remark-
ably low and there was no difference between the three periods. We
conclude that NCCaAc is a promising phosphate binder, since it is more
effective than ECCaAe and equally effective as CaCO1 (with a lower dose
elementary calcium). Tolerance is good during all three treatments.
Heart rate variability (HRV), autonomic neuropathy (AN), diurnal
blood pressure variation (DBPV) and cardiovascular mortality in patients
with end-stage renal disease. J.H. Assink, G. Kolsteec, .J.J.G. Ojjèrman and
HI G. Bib, Department of Internal Medicine, Dc Weezenlanden Hospital,
Control
Dose g Ca/day
Ca mmol/liter
P04 mmol/liter
PTH pmol/liter
Dietary P04 glday
Ca > 2.7 (events)
P04 > 2.5 (events)
1.55 0.15
2.44 0.03
1.83 0.1011 4
0.96 0.08
1.1%
2.1%
1.05 0.10
2.41 0.03
1.86 0.09
12 3
1.01 0.07
1.1%
1.1%
a P < 0.05 vs. control; 'P 0.05 vs. NCCaAe
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ZwolIe, The Netherlands. Decreased DBPV is associated with left ventric-
ular hypertrophy and an increased risk for cardiovascular complications.
We performed 24 hour blood pressure measurement, with a Spacelab
20907 in 20 ESRD patients (10 HD, 10 CAPD). AN was tested with the
O'Brien test set. HRV based on spectral analysis of 24 hour Holter ECG
registration was determined in 14 of these subjects (6 HD, 8 CAPD).
Impaired DBPV was defined as a day time/night time variability of <10%.
Eleven subjects (5 HD, 6 CAPD) showed an impaired DBPV, all subjects
had decreased HRV, and nine patients showed at least one sign of AN.
After 2 years of follow-up, 3 patients (2 CAPD, I HD) died because of
cardiovascular diseases. Five died because of sepsis or malignancy.
Although 5 of those patients (3 HD, 2 CAPD) had AN and 5 had DBPV
(4 HD, I CAPD), no relationship could he found (P = 0.7203; P = 0.3482)
for respiratory AN and DBPV. Mortality in patients with ESRD was high,
but is apparently not related with AN and/or DBPV. This might be
explained by the high proportion of death by infection diseases. We
therefore conclude that a decreased HRV, AN and impaired DBPV are
very common in subjects with end-stage renal disease. The group of
patients we studied appears to be too small to correlate these factors to
eventual cardiovascular mortality after 2 years follow-up.
The use of creatinine kinetics as a method for lean body mass
estimation in healthy controls and peritoneal dialysis (PD) patients: A
comparison with other techniques. H.F.H. Bndez, J. Roos, A.J.M. Donker,
and P.M. ter Wee, Departments of Nephrolo and Nuclear Medicine,
Academic Hospital Vrije Universiteit, Amsterdam, The Netherlands. Several
authors have used daily creatinine excretion to assess lean body mass
(LBM) as an indicator of the nutritional status in normals and in dialysis
patients. We compared the results of the LBM estimation by creatinine
kinetics (CK) with dual-energy x-ray absorptiometiy (DEXA; the gold
standard in healthy subjects), bioelectrical impedance analysis (BIA), and
anthropometric measurements [skinfolds (SF) and midarm muscle cir-
cumference (MAMC) in 8 healthy volunteers and in 14 stable PD
patients. In controls LBM estimation by CK correlated significantly with
DEXA (r2 = 0.61) and BIA (r2 = 0.52). A much stronger correlation,
however, was found between DEXA and BIA (r2 = 0.98), DEXA and SF(r2 = 0.98), and between BIA and SF (r2 = 0.98). In PD patients, CK
correlated significantly solely with DEXA (r2 = 0.39, P < 0.05) and
MAMC (r2 = 0.57, P < 0.01). The agreement (mean difference 2 SD) of
LBM estimation by CKwith DEXA, however, was very poor (—5.5 16.4
kg). In the patient group the strongest correlation coefficient (r2 = 0.83)
and the best agreement (mean difference 2 SD = —1.4 6.1 kg) was
found between LBM estimation by BIA and SF measurement. It is
concluded that, in contrast with the normal situation, the different tests
used to assess LBM have a weak correlation coefficient and poor
agreement when used in PD patients. The most useful tests for LBM
estimation in PD patients seem to he DEXA, skinfolds measurement, and
BIA. Compared to these methods, creatinine kinetics and MAMC ap-
peared to be less useful for the assessment of nutritional status in PD
patients.
Better survival on intermittent versus continuous hemodialysis in acute
renal failure. E. Hoste, R. Vanholder, J. Decruyenaere, C. Dc Deyne, F.
Colardyn, N. Lameire, and S. Ringoii; Departments of Nephrology and
Intensive Care, University Hospital, Gent, Belgium. Intermittent hemodial-
ysis of intensive care patients may cause hemodynamic problems. Contin-
uous dialysis techniques, such as CAVII/D or CVVH/D, have been
introduced to reduce these problems. Existing data comparing the survival
rate of patients treated with continuous and intermittent dialysis are,
however, scarce and conflicting. In addition, data have not always been
correlated to clinical condition. The present retrospective study comprises
231 intensive care patients with acute renal failure (ARF) and compared
the patients survival in continuous dialysis (N = 83) and intermittent
dialysis (N = 148) patients in relation to: (I) preexisting disease, (2)
contributing factors to ARE, (3) the Apache 11 score at the day of
admission on intensive care and at the day of ARF diagnosis, and (4) the
number of organ failure (coagulation abnormalities, need for vasopressors
or ventilation, liver or heart failure). Mean age of the intermittent dialyzed
patients was 61.0 14.5 years, and that of the continuously dialyzed
patients was 55.1 14.6 years (P = 0.0036). Global survival rate was 35%.
Intermittent dialysis had a better survival rate compared to continuous
dialysis (45.9% versus 15.6%; P < 0.0001). There was a trend towards a
higher presence of sepsis (86% vs. 72%; P = 0.07) and use of aminogly-
cosides (37% vs. 20%; P = 0.06) prior to the development of ARF in
continuous dialysis patients. Cardiac failure, contrast- and pigment-
induced ARF was not significantly different in both groups of patients.
Continuous and intermittent dialysis patients had a comparable mean
Apache 11 score on admission (27.1 9.2 vs. 28.1 8.7) and at the time
of developing ARF (29.9 8.3 vs. 29.1 8.0). Continuously dialyzed
patients had more coagulation abnormalities (56% vs. 26%; P = 0.002),
elevated bilirubin (75% vs. 51%; P = 0.01), need for ventilation (98% vs.
72%; P < 0.0001) and vasopressors (94% vs. 64%; P < 0.0001) than
patients treated with intermittent dialysis. We conclude that patients with
ARF in the intensive care unit treated with intermittent dialysis had a
better survival rate than patients treated with continuous dialysis, despite
being older and having a similar mean Apache II score, on admission and
at the day of ARF diagnosis. The difference in survival rate can, however,
entirely be explained by the worse clinical condition and the higher
frequency of multi-organ failure of continuously dialyzed patients. There-
fore, the Apache II score was not very helpful in predicting the outcome.
Heparin use in continuous renal replacement procedures: The struggle
between filter coagulation and patient hemorrhage. P.C. Chang, K van c/c
Wetering, R.G.J. Westendoip, HG. van der Hoeven, B. Stolk, and H.D.M.
Feuth, Department of Nephrology, Leiden University Hospital, Leiden, The
Netherlands. The evaluation of heparin use as an anticoagulant in Contin-
uous arteriovenous hemodiafiltration (CAVHD) was the focus of this
study. From 1991 through 1994, we studied filter survival and hemorrhagic
complications during 240 filter periods in 78 critically ill patients, treated
with CAVHD, with special emphasis on heparin dose, use of coumarins,
systemic activated partial thromboplastin time (APTI), platelet count,
mean arterial blood pressure (MAP), decreases in MAP, and the type of
filter used. One hundred forty-one filters (59%) were disconnected
because of coagulation. The mean survival of Multiflow AN69 filters was
half of FH66 filters. A total of 48 hemorrhagic complications occurred, of
which three patients died at APTT values of 39, 48 and 56 seconds,
respectively. After adjustment for MAP, decreases in MAP, platelet count
and the type of the filter, the risk for filter coagulation decreased by 25%
(relative risk 0.77 95% CI 0.68—0.85) for each ten seconds increase in
APTF, while the risk for patient hemorrhage increased by 50% (relative
risk 1.57, 95% CI 1.38—1.64). Filter coagulation and patient hemorrhages
occurred independently of the administered dose of heparin. Concurrent
use of coumarines prolonged filter survival, without increasing the inci-
dence rate of patient hemorrhage. In conclusions, the systemic APTT is a
good predictor of the risk for filter coagulation and patient hemorrhage.
Safety and efficacy of heparin therapy seem optimal at an AP'IT between
35 and 45 seconds.
Natural course of renal function in glycogen storage disease type I. J.P.
Rake, R. T Gansevoort, W C. C. Reitsma-Bierens, G. Visser, and G. PA. Smit,
Beatrix Children s Clinic, University Hospital, Groningen, The Netherlands.
After the occurrence of end-stage renal failure in an older patient with
glycogen storage disease type I (GSD I; incidence 1:200,000), we started to
investigate prospectively renal function in these patients. Included in a
transversal study were 34 patients who consecutively attended our out-
patient department from 1985 through 1994. Mean values of GFR, ERPF
and mean arterial pressure (MAP) among different age groups are shown
in the table, together with the percentage of patients with microalbumin-
urla (urinary albumin/creatinine ratio > 2.5 mg/mmol) or proteinuria
(urinary protein/ereatinine ratio > 20 mg/mmol).
Age group years <5 5—10
Patient N 8
GFR ml/min/1.73 rn2 150
ERPF mI/mm/I. 73 2h 637
MAP mm Hg 78
Microalbuminuria % 0
Proteinuria % 0
a '25T-iothalamate; 31I-hippuran
These data indicate that in GSD I patients, unlike in healthy peers, body
surface corrected GFR and ERPF increase until the age of 10 to 15 years.
Thereafter, a decline in renal function is observed. This course of renal
function contrasts with the pattern previously observed in GSD I patients,
10—15 15—20 >20
9
173
795
82
17
0
6
211
1106
85
40
0
6 4
171 134
840 776
86 91
75 75
0 50
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suggesting only a steady deterioration in GFR. With increasing age
m icroalbuminuria appears, progressing to proteinuria. Blood pressure
rises as in the healthy peers. To correct for possible time-dependent bias
in transversal studies, 16 of these patients were also studied longitudinally,
confirming the above observations. Surprisingly, this is a natural history of
renal function similar to that observed in patients with diabetes mellitus
(DM). However, whereas DM is characterized by hyperglycemia, GSD I
patients are hypoglycemic per se. We conclude that, since life expectancy
of GSD I patients improves due to better treatment, it has to be expected
that renal insufficiency will become an important clinical problem in these
patients. Furthermore, the observed natural course of non-linearity in
GFR will make it difficult to assess the result of therapy in long-term
intervention studies.
Glomerular permselectivity and skin capillary permeability are disso-
ciated in non-diabetic nephrotic patients. M.H. Hemmelde,; J. Jager, D. de
Zeeuw, R.P.F. Dullaart, A.]. Smit, and P.E. de Jong, GIDS, Department of
Medicine, University Hospital, Groningen, the Netherlands. Urinary protein
loss is associated with an increased risk of cardiovascular morbidity. It has
been suggested that both renal and extrarenal vascular pathology is the
result of generalized microvascular dysfunction. Accordingly, we recently
showed an increased transcapillary leakage of fluorescein sodium (FS) in
the ankle skin of 9 diabetic type I patients with microalbuminuria
compared to 9 normoalbuminuric diabetics and 9 healthy controls [median
(95% CI); 17.4 (16.2—19.6) vs. 14.4 (13.2—16.8) and 9.7 (9.1—11.0) 10%
see; P < 0.0051, as measured by a modified skin fluorophotometry
technique and expressed as the area under the relative fluorescence versus
time curve during the first 240 seconds (adapted from Bollinger et al). To
analyze whether impaired glomerular size and/or charge selectivity in
non-diabetic proteinuria is also associated with increased peripheral
microvascular permeability, we performed measurements of renal frac-
tional dextran clearances, renal pancreas- versus salivary-amylase clear-
ance ratio (PA/SA ratio), and transcapillary leakage of FS in II untreated
non-diabetic patients with nephrotic range proteinuria (3—21 g/day) and 14
healthy controls. Both groups had comparable age, gender distribution,
and body surface area. A loss of size selectivity was present in nephrotic
patients compared to controls as reflected by a decreased clearance of
dextran in the range of 30—46 A (P < 0.05) and an increased clearance of
dextran of 62—66 A (P < 0.05). Furthermore, the PAJSA ratio of 1.15
(0.88—1.43) in nephrotics was lower than the ratio of 1.98 (1.68—2.27) in
controls (P < 0.005), which reflects an impaired charge-selectivity. How-
ever, transcapillary leakage of FS was not different between both groups
[10.0 (7.3—12.7) vs. 9.0 (7.2—10.8) 10% see; P > 0.05]. No significant
correlation between proteinuria, dextran clearances, and PAJSA ratio with
transcapillaiy leakage of FS could be demonstrated in nephrotic patients.
In conclusion, in contrast to diabetic microalbuminuria, the increased
renal permeability to proteins in non-diabetic proteinuria is not associated
with an increased peripheral transcapillary permeability. This observation
suggests a dissociation in extrarenal microvascular function between
diabetic and non-diabetic renal disease. Further studies are necessary to
analyze whether other extrarenal microvascular functions in non-diabetic
proteinuria are impaired and thus may contribute to coexistent cardiovas-
cular morbidity.
The contribution of the transcellular pores to the total ultrafiltration
coefficient (UFC) o[ the peritoneal membrane in stable CAPD. MM.
Pannekeet and 1?. T. Krediet, Department of Nephrology, Academic Medical
Center, Amsterdam, the Netherlands'. Ultrafiltration induced by hyperos-
molar glucose-based dialysate solutions is composed of both convective
transport through small intercndothclial pores, and transport through
transcellular (water only) pathways. These transcellular pores are proba-
bly only involved when an osmolality gradient is present. As a conse-
quence, the colloid osmotic pressure of isosmolar glucose polymers based
solutions will almost exclusively be exerted across the small interendothe-
hal pores. This implies that the UFC of the transcellular pores (UFCtp)
can he calculated from the difference between the total UFC, calculated
with a hyperosmolar glucose solution (glucose 3.86%), and the UFC of
the small pores, obtained with glucose polymers (icodextrin, UFCsp):UFCtot = UFCsp + UFCtp. In the present study standard peritoneal
permeability analyses were performed with these two solutions in 10 stable
CAPD patients. The UFCs were calculated from the maximal transcapil-
lary ultrafiltration rate (TCUFR) in the first minute of the dwell, divided
by the sum of the hydrostatic pressure gradient (P), the colloid osmotic
pressure gradient (oll, with a- being the reflection coefficient), and the
cristalloid Osmotic gradient (o-O). P was fixed at 9 mm Hg. Serum
albumin (SA) was assumed to determine the capillary colloid osmotic
pressure for 75%. To this value, 0.4 mOsmol was added because of
Gibbs-Donnan equilibrium. The osmotic pressure exerted by glucose was
calculated from the osmolality of the dialysate multiplied with a- and 19.3
(according to van't Hoffs law) and the pressure exerted by icodextrin from
the dialysate icodextrin concentration (DIC) multiplied with cr and 19.3.
For n-of icodextrin 0.797 was estimated, and the other a-values were 1.0
for albumin and 0.03 for glucose. This yielded:
TCUFRJ_1 mm (3.86%) TcUFRQ_1 (Icodextrin)UF =
283 — 0.38SA — 0.58 Osmol 0.77D1C — 0.38SA + 1.28
The total UFC was 0.18 0.04 mI/mm (mean SEM). The transcellular
pores contributed to this value for a mean of 50.5%, ranging from 0 to
85% in individual patients. A negative correlation was present between
duration of CAPD treatment and the total UFC (r =
—0.68, P < 0.05),
which could be attributed to a decrease in UFCP (r =
—0.66, P < 0.05),
but not to the UFC (r =
—0.12, NS). Peritonitis incidence was not
related to any of the UFCs. The concentration gradient of sodium,
corrected for diffusion, was positively related to the TCUFRI in the first
hour of the dwell (r = 0.66, P < 0.04), but not to the TCUFRS (r = 0.09,
NS). It can be concluded that the transcellular pathway accounts for
approximately 50% of the ultrafiltration when hyperosmolar dialysis
solutions are used. The UFC decrease with the duration of CAPD is
probably caused by an impairment of the transcellular route, whereas the
intercellular pathway remains intact. Both sodium sieving and UFC,
measure transcellular water transport.
Effect of an acute 5HT2 antagonism on the autoregulation of renal
blood flow in cyclosporine treated rats. M. Verbeke, J. Van de Voorde, and
N. Lameire, Departments of Histology, Normal and Pathological Physiology,
and Nephrology, University of Gent, Gent, Belgium. The beneficial effect of
a serotonin 5HT2 antagonist, ketanserin, on the autoregulation (AR) of
renal blood flow (RBF) in post-isehemic kidneys was found in a previous
study. The aim of the present study was to analyze whether ketanscrin
could ameliorate impaired AR in rats (± 300 g) after a 10 day cyclosporine
(CS) treatment (20 mg/kg/day p.o.). At day 11, RBF was recorded using an
electromagnetic flow probe, during a stepwise (5 mm Hg) lowering of the
RPP from 110 mm Hg down to 70 mm Hg, by means of a gradual
compression of the aorta. AR was lost in all CS-treated animals (N = 8).
After a control AR measurement, ketanserin was administered (0.05
mg/kg iv. bolus, followed by 0.1 mg/kg/hr i.v. infusion) during 1 hour and
AR was reanalyzed while continuing the infusion. Basal RBF values were
3.59 0.24 and 3.95 0.35 mI/mm (NS) before and during ketanserin,
respectively. The slope of the AR curve was significantly modified in the
pressure interval 110—95 mm Hg (from 0.985 0.066 before ketanserin to
0.157 0.041 during ketanserin; P < 0.0001). At each step of the lowered
RPP, RBF (%) was significantly higher during ketanserin. Clearances
were performed in CS-treated rats, before and during an identical
ketanserin administration (N = 8). Ketanserin did not improve CS-
induced impairment of glomerular filtration rate (1.49 0.59 mllmin
before vs. 1.38 0.15 mI/mm during ketanserin) and effective renal
plasma flow (4.07 (1.59 mI/mm vs. 4.05 0.48 mI/mm). In conclusion,
AR of RBF is lost during CS-treatment of rats. Since the AR reappears
after a 1 hour administration of a 51 IT2 antagonist, it is suggested that
serotonin is involved in the CS-induced loss of AR. On the other hand, no
improvement of CS-induced renal dysfunction is obtained with acute
administration of ketanserin.
Do patients with angiographically proven access stenosis have low
access blood flow? F. T.J. Boereboom, P.J. Bosinan, P.J. Blankes fl/n, and
HA. Koomans, Departments of Nephrology and Vascular Surgery, University
Hospital Utrecht, Utrecht, The Netherlands. Access thrombosis is an impor-
taut problem in the management of hemodialysis patients. It is frequently
associated with the existence of an access stenosis. Venous pressure (>150
mm Hg) measured at dialyzer blood flow 200 mI/mm (VP200) is used as
an indicator for access stenosis. The difference in venous pressure at
dialyzer blood flow 0 and 400 mI/mm (bVPO—400) is even more sensitive
than VP200 for detection of access stenosis (ISN 1995). However, it is not
Stenosis or high venous pressure per ce, hut low volume blood flow that
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predisposes for access thrombosis. Recently, we validated a newly devel-
oped device for access volume flow measurement, which is based on the
Fick principle of dilution (Transonic Hemodialysis Monitor). The aim of
the present study was to measure access volume blood flow in 36 patients
(all secondary bridge grafts, 13 PTFE, 23 homologous veins) who also
underwent an angiogram. In 19 patients the angiogram revealed a
significant stenosis in the venous outflow tract (group A), whereas in 17
patients the angiogram was normal (group B). In group A as compared
with group B VP200 was 137 37 and 93 31 mm Hg (P < 0.001) and
VP0-400 was 192 32 and 148 35 mm Hg (P < 0.001). Access volume
flow was 637 387 mI/mm (range 166—1439, median 625) in group A and
1157 354 mI/mm (range 598—1740, median 977) in group B (P < 0.001)
and vascular access resistance (calculated from the arterial pressure and
the vascular access volume flow) was 0.199 0.162 and 0.096 0.037 mm
Hg mm/mi, respectively (P < 0.01). Access volume blood flow was
especially low in patients with stenosis and low blood pressure. In
conclusion: VP200, bVPO—400 and vascular access resistance are higher,
but access volume blood flow was lower in patients with access stenosis.
However, some of the patients with stenosis still have a high access blood
flow, indicating that not all patients with stenosis are at risk for thrombo-
sis. Access volume flow measurement is a more suitable tool for functional
access surveillance than venous pressure measurement. Studies are
needed to establish below which level of volume flow the risk of
thrombosis increases.
